Drug Profile


Alternative Names: JNJ-63623872; JNJ-872; VX 787

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Janssen Pharmaceuticals; Vertex Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 07 Mar 2017 Chemical structure information added
  • 13 Sep 2016 Janssen-Cilag International initiates a phase I trial in Influenza-A virus infections (In volunteers) in Belgium (PO, Tablet) (NCT02860806)
  • 05 Aug 2016 Janssen-Cilag International plans a phase I trial in Healthy volunteers in USA and Belgium (IV, Infusion and PO, Tablet) (NCT02860806)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top